202 related articles for article (PubMed ID: 36399512)
1. The apparent interferon resistance of transmitted HIV-1 is possibly a consequence of enhanced replicative fitness.
Sugrue E; Wickenhagen A; Mollentze N; Aziz MA; Sreenu VB; Truxa S; Tong L; da Silva Filipe A; Robertson DL; Hughes J; Rihn SJ; Wilson SJ
PLoS Pathog; 2022 Nov; 18(11):e1010973. PubMed ID: 36399512
[TBL] [Abstract][Full Text] [Related]
2. In vitro replicative fitness of early Transmitted founder HIV-1 variants and sensitivity to Interferon alpha.
Ashokkumar M; Sonawane A; Sperk M; Tripathy SP; Neogi U; Hanna LE
Sci Rep; 2020 Feb; 10(1):2747. PubMed ID: 32066770
[TBL] [Abstract][Full Text] [Related]
3. The Envelope Gene of Transmitted HIV-1 Resists a Late Interferon Gamma-Induced Block.
Rihn SJ; Foster TL; Busnadiego I; Aziz MA; Hughes J; Neil SJD; Wilson SJ
J Virol; 2017 Apr; 91(7):. PubMed ID: 28100611
[TBL] [Abstract][Full Text] [Related]
4. Heterosexual Transmission of Subtype C HIV-1 Selects Consensus-Like Variants without Increased Replicative Capacity or Interferon-α Resistance.
Deymier MJ; Ende Z; Fenton-May AE; Dilernia DA; Kilembe W; Allen SA; Borrow P; Hunter E
PLoS Pathog; 2015 Sep; 11(9):e1005154. PubMed ID: 26378795
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the Plasmacytoid Dendritic Cell Response to Transmitted/Founder and Nontransmitted Variants of HIV-1.
Schwartz JA; Zhang H; Ende Z; Deymier MJ; Lee T; Singer J; Mazzulli T; Hunter E; Ostrowski MA
J Virol; 2018 Oct; 92(19):. PubMed ID: 29997203
[TBL] [Abstract][Full Text] [Related]
6. Antithetic effect of interferon-α on cell-free and cell-to-cell HIV-1 infection.
Kumata R; Iwanami S; Mar KB; Kakizoe Y; Misawa N; Nakaoka S; Koyanagi Y; Perelson AS; Schoggins JW; Iwami S; Sato K
PLoS Comput Biol; 2022 Apr; 18(4):e1010053. PubMed ID: 35468127
[TBL] [Abstract][Full Text] [Related]
7. Relative resistance of HIV-1 founder viruses to control by interferon-alpha.
Fenton-May AE; Dibben O; Emmerich T; Ding H; Pfafferott K; Aasa-Chapman MM; Pellegrino P; Williams I; Cohen MS; Gao F; Shaw GM; Hahn BH; Ochsenbauer C; Kappes JC; Borrow P
Retrovirology; 2013 Dec; 10():146. PubMed ID: 24299076
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic properties of transmitted founder HIV-1.
Parrish NF; Gao F; Li H; Giorgi EE; Barbian HJ; Parrish EH; Zajic L; Iyer SS; Decker JM; Kumar A; Hora B; Berg A; Cai F; Hopper J; Denny TN; Ding H; Ochsenbauer C; Kappes JC; Galimidi RP; West AP; Bjorkman PJ; Wilen CB; Doms RW; O'Brien M; Bhardwaj N; Borrow P; Haynes BF; Muldoon M; Theiler JP; Korber B; Shaw GM; Hahn BH
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6626-33. PubMed ID: 23542380
[TBL] [Abstract][Full Text] [Related]
9. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
10. The human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted viruses.
Kong X; West JT; Zhang H; Shea DM; M'soka TJ; Wood C
J Virol; 2008 Dec; 82(23):11609-18. PubMed ID: 18786994
[TBL] [Abstract][Full Text] [Related]
11. Unique Phenotypic Characteristics of Recently Transmitted HIV-1 Subtype C Envelope Glycoprotein gp120: Use of CXCR6 Coreceptor by Transmitted Founder Viruses.
Ashokkumar M; Aralaguppe SG; Tripathy SP; Hanna LE; Neogi U
J Virol; 2018 May; 92(9):. PubMed ID: 29491151
[TBL] [Abstract][Full Text] [Related]
12. Interferon inhibits the replication of HIV-1, SIV, and SHIV chimeric viruses by distinct mechanisms.
Korth MJ; Taylor MD; Katze MG
Virology; 1998 Aug; 247(2):265-73. PubMed ID: 9705919
[TBL] [Abstract][Full Text] [Related]
13. Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness.
Iyer SS; Bibollet-Ruche F; Sherrill-Mix S; Learn GH; Plenderleith L; Smith AG; Barbian HJ; Russell RM; Gondim MV; Bahari CY; Shaw CM; Li Y; Decker T; Haynes BF; Shaw GM; Sharp PM; Borrow P; Hahn BH
Proc Natl Acad Sci U S A; 2017 Jan; 114(4):E590-E599. PubMed ID: 28069935
[TBL] [Abstract][Full Text] [Related]
14. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
15. Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption.
Gondim MVP; Sherrill-Mix S; Bibollet-Ruche F; Russell RM; Trimboli S; Smith AG; Li Y; Liu W; Avitto AN; DeVoto JC; Connell J; Fenton-May AE; Pellegrino P; Williams I; Papasavvas E; Lorenzi JCC; Salantes DB; Mampe F; Monroy MA; Cohen YZ; Heath S; Saag MS; Montaner LJ; Collman RG; Siliciano JM; Siliciano RF; Plenderleith LJ; Sharp PM; Caskey M; Nussenzweig MC; Shaw GM; Borrow P; Bar KJ; Hahn BH
Sci Transl Med; 2021 Jan; 13(576):. PubMed ID: 33441429
[TBL] [Abstract][Full Text] [Related]
16. Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness.
Weber J; Weberova J; Carobene M; Mirza M; Martinez-Picado J; Kazanjian P; Quiñones-Mateu ME
J Virol Methods; 2006 Sep; 136(1-2):102-17. PubMed ID: 16690137
[TBL] [Abstract][Full Text] [Related]
17. An
Ashokkumar M; Sonawane A; Sathiyamani B; Esakialraj L BH; Hanna LE
Data Brief; 2020 Apr; 29():105365. PubMed ID: 32195300
[TBL] [Abstract][Full Text] [Related]
18. Transmission of Multiple HIV-1 Subtype C Transmitted/founder Viruses into the Same Recipients Was not Determined by Modest Phenotypic Differences.
Song H; Hora B; Giorgi EE; Kumar A; Cai F; Bhattacharya T; Perelson AS; Gao F
Sci Rep; 2016 Dec; 6():38130. PubMed ID: 27909304
[TBL] [Abstract][Full Text] [Related]
19. [ADS-J1 antagonizes semen-derived enhancer of virus infection-mediated enhancement of transmitted founder HIV-1 and its matched chronic control strain infection].
Liu HM; Ma NN; Luo C; Yuan SY; Liu FL; Yao XG; Zhou CQ; Zou M
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Feb; 38(2):211-216. PubMed ID: 29502062
[TBL] [Abstract][Full Text] [Related]
20. Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.
Pingen M; Wensing AM; Fransen K; De Bel A; de Jong D; Hoepelman AI; Magiorkinis E; Paraskevis D; Lunar MM; Poljak M; Nijhuis M; Boucher CA;
Retrovirology; 2014 Nov; 11():105. PubMed ID: 25575025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
